Gene therapy, CRISPR, synthetic biology, and emerging platforms—what's real, what's hype, and what translates.
Novo Nordisk has entered a significant partnership with Vivtex, a biotech startup co-founded by MIT professor Robert Langer, to develop oral medications targeting obesity and diabetes.
Novo Nordisk has entered a significant partnership with Vivtex, a biotech startup co-founded by MIT professor Robert Langer, to develop oral medications targeting obesity and diabetes.
READ MORE
Slate Medicines has raised $130 million to push forward a promising antibody that targets PACAP, a key protein implicated in migraines.
Korsana Biosciences has secured $175 million to advance its novel Alzheimer’s drug, which utilizes a brain-penetrating antibody platform aimed at overcoming the blood-brain barrier challenges faced by neurodegenerative therapies.
Next-generation obesity treatments are emerging to overcome the limitations of GLP-1 therapies, focusing on muscle preservation, oral administration, and combination approaches.
Korsana Biosciences emerges as a significant player in Alzheimer’s disease therapeutics with substantial funding aimed at enhancing brain delivery and reducing adverse effects related to amyloid imaging.
Ocular Therapeutix’s experimental wet AMD drug Axpaxli has outperformed Regeneron’s Eylea in a pivotal Phase 3 trial, positioning it for an upcoming FDA submission.
Compass Pathways’ investigational psilocybin therapy, COMP360, has demonstrated positive effects in patients with severe depression across two clinical trials, showcasing potential as a novel psychiatric treatment.
The year 2026 may represent a decisive moment for American leadership in biotechnology innovation amidst current political challenges.
Vertex Pharmaceuticals and CRISPR Therapeutics anticipate near tripling revenues from Casgevy gene therapy in 2026 as patient access expands, signaling growing market potential for this novel treatment.
The Mayo Clinic Platform expresses reservations on the utility of de-identified health data for pharmaceutical companies and third parties, advocating for integrated approaches that combine data with clinical expertise for drug development.
BridgeBio Pharma announced statistically significant results from its Phase 3 trial for infigratinib, an oral FGFR3 inhibitor targeting achondroplasia, the most common form of dwarfism. The new data positions the drug for regulatory submissions with the FDA later this year.
